Payment overview · 2025
General Payments
$97.28
5 reported records · 4 companies
Healthcare provider profile · identity verified
Trevor Rohm, MD
Allopathic & Osteopathic Physicians|Family Medicine · HEREFORD, TX · NPI 1780723791
Verified facts
What the public records show
CMS Open Payments records show Trevor Rohm, MD received $97.28 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.89 | 34.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.60 | 26.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.94 | 19.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 19.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $78.43 | 4 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 533 | 89 |
| Gabapentin | Gabapentin | 467 | 83 |
| Potassium Chloride | Potassium Chloride | 439 | 72 |
| Lisinopril | Lisinopril | 395 | 72 |
| Metformin Hcl | Metformin Hcl | 391 | 77 |
| Furosemide | Furosemide | 326 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 49 |
| Omeprazole | Omeprazole | 256 | 55 |
| Tramadol Hcl | Tramadol Hcl | 247 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 244 | 34 |
| Carvedilol | Carvedilol | 236 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 227 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 36 |
| Alendronate Sodium | Alendronate Sodium | 213 | 56 |
| Losartan Potassium | Losartan Potassium | 209 | 34 |
| Trazodone Hcl | Trazodone Hcl | 189 | 24 |
| Eliquis | Apixaban | 182 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 42 |
| Meloxicam | Meloxicam | 174 | 33 |
| Buspirone Hcl | Buspirone Hcl | 168 | 28 |
| Sertraline Hcl | Sertraline Hcl | 167 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 24 |
| Donepezil Hcl | Donepezil Hcl | 163 | 20 |
| Glipizide Er | Glipizide | 159 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 39 |
| Allopurinol | Allopurinol | 137 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 134 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 35 |
| Ozempic | Semaglutide | 126 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 25 |
| Alprazolam | Alprazolam | 123 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 118 | 31 |
| Simvastatin | Simvastatin | 118 | 19 |
| Famotidine | Famotidine | 117 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 19 |
| Baclofen | Baclofen | 106 | suppressed |
| Glipizide | Glipizide | 106 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 15 |
| Celecoxib | Celecoxib | 102 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 19 |
| Prednisone | Prednisone | 95 | 62 |
| Jardiance | Empagliflozin | 91 | 16 |
| Cephalexin | Cephalexin | 87 | 54 |
| Memantine Hcl | Memantine Hcl | 86 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | suppressed |
| Lactulose | Lactulose | 75 | 18 |
| Pregabalin | Pregabalin | 72 | 15 |
| Levetiracetam | Levetiracetam | 69 | suppressed |
| Spironolactone | Spironolactone | 69 | 16 |
| Montelukast Sodium | Montelukast Sodium | 68 | 17 |
| Propranolol Hcl | Propranolol Hcl | 67 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 15 |
| Metformin Hcl Er | Metformin Hcl | 57 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 11 |
| Sucralfate | Sucralfate | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 40 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | suppressed |
| Naproxen | Naproxen | 50 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 24 |
| Nystatin | Nystatin | 46 | 26 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 30 |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 41 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Glimepiride | Glimepiride | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 35 | 12 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Estazolam | Estazolam | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.28 · 5 records | ABBVIE INC. | FARXIGA, JARDIANCE, QULIPTA, UBRELVY, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error